TY - JOUR
T1 - Antipsychotics in Alzheimer’s Disease
T2 - Current Status and Therapeutic Alternatives
AU - Maziero, Maria Paula
AU - Rocha, Natalia P.
AU - Teixeira, Antonio L.
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - Psychosis and hyperactive behaviors, such as agitation and wandering, affect a significant proportion of patients with Alzheimer’s disease (AD). These symptoms are often treated with antipsychotics, usually in an off-label approach. This mini-review provides an updated perspective on the pharmacological approach for the neuropsychiatric symptoms (NPS) in AD. The results of new studies have provided a better understanding of AD-related NPS management, but high-quali-ty evidence still needs to be obtained. Herein, we argue for a more cautious approach to the use of antipsychotics in AD and highlight the importance of exploring alternative treatments for NPS. By doing so, we can ensure that patients with AD receive optimal care that is both effective and safe.
AB - Psychosis and hyperactive behaviors, such as agitation and wandering, affect a significant proportion of patients with Alzheimer’s disease (AD). These symptoms are often treated with antipsychotics, usually in an off-label approach. This mini-review provides an updated perspective on the pharmacological approach for the neuropsychiatric symptoms (NPS) in AD. The results of new studies have provided a better understanding of AD-related NPS management, but high-quali-ty evidence still needs to be obtained. Herein, we argue for a more cautious approach to the use of antipsychotics in AD and highlight the importance of exploring alternative treatments for NPS. By doing so, we can ensure that patients with AD receive optimal care that is both effective and safe.
KW - Alzheimer’s disease
KW - agitation
KW - antipsychotics
KW - hyperactive behaviors
KW - neuropsychiatric symptoms
KW - psychosis
UR - https://www.scopus.com/pages/publications/85187429240
UR - https://www.scopus.com/pages/publications/85187429240#tab=citedBy
U2 - 10.2174/0115672050287534240215052417
DO - 10.2174/0115672050287534240215052417
M3 - Short survey
C2 - 38409713
AN - SCOPUS:85187429240
SN - 1567-2050
VL - 20
SP - 682
EP - 691
JO - Current Alzheimer Research
JF - Current Alzheimer Research
IS - 10
ER -